Explanipedia

Pan-microbial serological repertoire as a biomarker of immunotherapy response in hepatocellular carcinoma Open

Shay Behrens, Whitney Leet, Limin Wang, Mahler Revsine, Evan Maestri , et al. · 2025

Immune checkpoint inhibition (ICI) has become a first-line treatment strategy for advanced hepatocellular carcinoma (HCC). However, treatment efficacy remains varied, and there are no reliable biomarkers of response. We used phage immunopr…

SPP1 + macrophages cause exhaustion of tumor-specific T cells in liver metastases Open

Rajiv Trehan, Patrick Huang, Xiao Bin Zhu, Xin Wang, Marlaine Soliman , et al. · 2025

Neue Ansätze in der Immuntherapie gastrointestinaler Tumoren Open

Bernd Heinrich, Tim F. Greten · 2025

Erratum: Disparities in Cholangiocarcinoma Research and Trials: Challenges and Opportunities in the United States Open

Oyepeju Abioye, Oyepeju Abioye, Tim F. Greten, Cecilia Monge · 2025

Disparities in Cholangiocarcinoma Research and Trials: Challenges and Opportunities in the United States Open

Oyepeju Abioye, Oyepeju Abioye, Tim F. Greten, Cecilia Monge · 2025

Cancer disparities are well-established across measures of cancer incidence and mortality. Cholangiocarcinoma, a common hepatic malignancy, is no exception to these inequities. Globally and within the United States, Asian, Hispanic, and In…

Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients Open

Jianzhou Chen, Antonin Lévy, Ai-Ling Tian, Xuehan Huang, Guoxin Cai , et al. · 2025

Hepatic immune environment differences among common mouse strains in models of MASH and liver cancer Open

Patrick Huang, Francisco Rodríguez-Matos, Jonathan Qi, Rajiv Trehan, Yuta Myojin , et al. · 2025

Our immune cell profiling study revealed that the liver immune environment can be quite different among common mouse strains both under healthy and pathologic states, such as steatohepatitis or neoplastic processes. Our results serve as a …

Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab Open

Yuta Myojin, Sepideh Babaei, Rajiv Trehan, Caitlin Hoffman, Noémi Kedei , et al. · 2025

Background Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. The combination of tremelimumab and durvalumab is now a standard treatment option for advanced HCC. Objective To study immune responses in HCC patien…

Erratum for: Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma Open

Ryan Bitar, Riad Salem, Richard S. Finn, Tim F. Greten, S. Nahum Goldberg , et al. · 2025

Liver Cancer Neuroscience: Regulating Liver Tumors via Selective Hepatic Vagotomy Open

Kylynda C. Bauer, Shadin Ghabra, Chi Ma, Lee Chedester, Tim F. Greten · 2024

Both the prevalence and mortality of liver cancers continue to rise. Early surgical interventions, including liver transplantation or resection, remain the only curative treatment. Nerves in the periphery influence tumor growth within visc…

Quantifying morphologic variations as an alternate to standard response criteria for unresectable primary liver tumors after checkpoint inhibition therapy Open

Laetitia Saccenti, Nicole Varble, Tabea Borde, Andrew S. Mikhail, Michael T. Kassin , et al. · 2024

Purpose The aim of this study was to assess the feasibility of quantifying morphologic changes in tumors during immunotherapy, as a reflection of response or survival. Methods and materials A retrospective single-center analysis was perfor…

Protocol for establishing liver tumors via ultrasound-guided intrahepatic injection prior partial hepatic resection in a mouse model Open

Shadin Ghabra, Rajiv Trehan, Francisco Rodríguez-Matos, Chi Ma, Tim F. Greten · 2024

Integration of circulating tumor DNA in biliary tract cancer: the emerging landscape Open

Joy Awosika, Cecilia Monge, Tim F. Greten · 2024

Precision medicine has emerged as a cornerstone in cancer treatment revolutionizing our approach across malignancies. Molecular profiling of biliary tract cancers (BTCs) has changed the treatment landscape positively by prolonging survival…

A Paradoxical Tumor Antigen Specific Response in the Liver Open

Rajiv Trehan, Xiao Bin Zhu, Patrick Huang, Xin Wei Wang, Marlaine Soliman , et al. · 2024

Functional tumor-specific CD8+ T cells are essential for an effective anti-tumor immune response and the efficacy of immune checkpoint inhibitor therapy. In comparison to other organ sites, we found higher numbers of tumor-specific CD8+ T …

Unveiling Disparities: Analyzing Hispanic Inclusion in Liver Cancer Research Databases in the United States Open

Gabriela Arroyo Figueroa, Tim F. Greten, Cecilia Monge · 2024

Primary liver cancer, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma was the sixth leading cause of cancer death in the United States in 2023. Hispanic people constitute approximately 19% of the nation’s total popul…

Innate-like T cells in liver disease Open

Albert Ying-Po Yang, Kilian Wistuba‐Hamprecht, Tim F. Greten, Benjamin Ruf · 2024

Hepatic artery infusion pump (HAIP) therapy in combination with targeted delivery of IL-12 for patients with metastatic colorectal cancer or intrahepatic cholangiocarcinoma: a phase II trial protocol Open

Jack H. Victory, Emily C. Smith, Carrie E. Ryan, Jacob Lambdin, Amber Leila Sarvestani , et al. · 2024

ClinicalTrials.gov (ID NCT05286814 version 2023-10-18); https://clinicaltrials.gov/study/NCT05286814?term=NCT05286814&rank=1.

Innate protection against intrarectal SIV acquisition by a live SHIV vaccine Open

Yongjun Sui, Thomas J. Meyer, Christine M. Fennessey, Brandon F. Keele, Kimia Dadkhah , et al. · 2024

Identifying immune correlates of protection is a major challenge in AIDS vaccine development. Anti-Envelope antibodies have been considered critical for protection against SIV/HIV (SHIV) acquisition. Here, we evaluated the efficacy of an S…

Abstract No. 338 Immuno-embolization with PD-L1 Checkpoint Inhibitor–Eluting Radiopaque “IMMUNO-Beads” in Woodchuck Hepatocellular Carcinoma Open

Andrew S. Mikhail, Michal Mauda‐Havakuk, Cody J. Peer, Tailang Yin, Ivane Bakhutashvili , et al. · 2024

Lineage and ecology define liver tumor evolution in response to treatment Open

Mahler Revsine, Limin Wang, Marshonna Forgues, Shay Behrens, Amanda J. Craig , et al. · 2024

The Gut Microbiome Controls Liver Tumors via the Vagus Nerve Open

Kylynda C. Bauer, Rajiv Trehan, Benjamin Ruf, Yuta Myojin, Mohamed-Reda Benmebarek , et al. · 2024

Liver cancer ranks amongst the deadliest cancers. Nerves have emerged as an understudied regulator of tumor progression. The parasympathetic vagus nerve influences systemic immunity via acetylcholine (ACh). Whether cholinergic neuroimmune …

Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma Open

Cecilia Monge, Changqing Xie, Yuta Myojin, Kelley Coffman, Donna Mabry Hrones , et al. · 2024

Background Current standard of care for advanced biliary tract cancer (BTC) is gemcitabine, cisplatin plus anti‐PD1/PD‐L1, but response rates are modest. The purpose of this study was to explore the efficacy and safety of durvalumab (anti‐…

VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial Open

Kelley Coffman, Yuta Myojin, Cecilia Monge, Changqing Xie, Donna Mabry Hrones , et al. · 2024

Background Microsatellite stable colorectal liver metastases (MSS CLM) maintain an immunosuppressive tumor microenvironment (TME). Historically, immune-based approaches have been ineffective. VB-111 (ofranergene obadenovec) is a geneticall…

Underrepresentation of Hispanics in clinical trials for liver cancer in the United States over the past 20 years Open

Cecilia Monge, Tim F. Greten · 2023

Importance Accurate representation of racial and ethnic population subgroups in clinical trials is fundamental to ensure universal effectiveness of new therapies as well as to decrease disparities in oncology care. Objective To determine w…

Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping Open

Sylvan C. Baca, Ji-Heui Seo, Matthew P. Davidsohn, Brad Fortunato, Karl Semaan , et al. · 2023

Adenosine A2a receptor inhibition increases the anti-tumor efficacy of anti-PD1 treatment in murine hepatobiliary cancers Open

Yuta Myojin, Justin McCallen, Chi Ma, Kylynda C. Bauer, Benjamin Ruf , et al. · 2023

Adenosine A2a receptor (A2aR)-expressing T cells in the liver increased in tumor-bearing mice and after anti-PD1 treatment. The combination of an A2aR inhibitor and anti-PD1 treatment had potent anti-tumor effects in two murine models of o…

Genome-wide profiling of transcription factor activity in primary liver cancer using single-cell ATAC sequencing Open

Amanda J. Craig, Maruhen Amir Datsch Silveira, Lichun Ma, Mahler Revsine, Limin Wang , et al. · 2023

988 Vagal-CD8+ T cell neuroimmune axis modulates liver cancer Open

Kylynda C. Bauer, Benjamin Ruf, Yuta Myojin, Mohamed-Reda Benmebarek, Chi Ma , et al. · 2023

Background Liver cancer remains the third leading cause of worldwide cancer-related deaths.¹ Despite clinical advances, established immunotherapies largely fail patients due to poor immune responses.^{1 2} Peripheral ner…

472 Anti-VEGF treatment amplifies immune checkpoint inhibitor induced immune responses by targeting B and regulatory T cells Open

Mohamed-Reda Benmebarek, Cihan Oguz, Benjamin Ruf, Yuta Myojin, Patrick Huang , et al. · 2023

Background We have previously reported early and unexpected results of an open label phase II trial treating patients with histologically confirmed hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) treated with anti-CTLA4 + anti-…

585 Ofranergene obadenovec (VB-111) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single-center, single-arm phase II trial Open

Kelley Coffman, Yuta Myojin, Cecilia Monge, Changqing Xie, Donna Mabry Hrones , et al. · 2023

Background Microsatellite stable colorectal liver metastases (MSS CLM) maintain an immunosuppressive tumor microenvironment (TME). Historically, immune-based approaches have been ineffective. VB-111 is a genetically-modified adenoviral vec…

Tim F. Greten YOU? Author Swipe